At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
I5T-MC-AACI: The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.
ATH-1017-AD-203: The purpose of this study is to determine the safety and tolerability of ATH-1017 in patients with mild to moderate Alzheimer's disease.